As the global burden of diabetes continues to climb, so too does the impact of its most feared complications—including diabetic foot ulcers (DFUs), infections, and amputations. While tight glycemic control has long been a cornerstone of diabetic foot prevention, emerging therapies are now offering benefits that go beyond glucose reduction.
In our newly accepted paper in Frontiers in Endocrinology (doi:10.3389/fendo.2025.1581403), my co-authors and I- led by my friend and mentee, Prof. Wuquan Deng of Chongqing, examine whether today’s novel glucose-lowering agents might provide unexpected help where it’s most needed—at the end of the limb.
Beyond Sugar: Three Classes, One Hope
Among the modern antihyperglycemic agents, three drug classes stand out for their pleiotropic effects:
- DPP-4 inhibitors (DPP-4is)
- GLP-1 receptor agonists (GLP-1RAs)
- SGLT2 inhibitors (SGLT2is)
Each has been lauded for cardiovascular and renal benefits. But could they also support wound healing and limb preservation?
Key Takeaways from the Review
🔹 GLP-1RAs and DPP-4is have shown the greatest promise in enhancing wound healing and possibly preventing diabetic foot complications. Several preclinical and clinical studies point to improved microvascular function, anti-inflammatory effects, and modulation of immune pathways conducive to healing.
🔹 SGLT2is, while excellent for cardiorenal protection, have yet to demonstrate consistent benefit for the diabetic foot. Some studies even raise concern for rare but serious risks, such as Fournier’s gangrene, which merit close attention.
Implications for Clinical Care
The upshot: Glycemic agents may do more than control glucose—they may shape wound trajectories. As clinicians, we’re entering an era where we can increasingly align metabolic therapy with limb preservation goals.
We believe future large-scale, limb-specific trials will be essential to validate these early findings. In the meantime, awareness of these adjunctive benefits may help personalize therapy in patients at risk of or recovering from diabetic foot wounds.
Indeed, for those of us working to prevent amputation and improve quality of life, these drugs may represent the “icing on the cake.”
Citation
Li Q, Yu S, Rui S, Lin X, Yuan Y, Armstrong DG, Xu Y, Deng W, “Novel Glucose-Lowering Agents That Benefit Diabetic Foot: Icing on the Cake,” Front. Endocrinol. 2025;16. doi: 10.3389/fendo.2025.1581403
Leave a Reply